Skip to main content

The New Profile of Drug-Resistant Tuberculosis in Russia A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science (2011) / Chapter Skim
Currently Skimming:

8 The Second-Line Drug Supply Chain
Pages 87-94

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 87...
... Presenters on the supply chain for second-line TB drugs described a new paradigm for the drug supply for drug-resistant TB and offered three different perspectives on MDR TB treatment and the drug supply chain in Russia.
Read the entire page →
From page 88...
... "The GLC was formed so that the new pilot projects did not increase the risk of MDR TB through poor-quality programs," said Zintl. "The committee controlled access and provided discounted prices for relatively limited supplies of quality-assured drugs." In 2006, WHO officially changed its policy to call for treatment of MDR TB patients in all countries with a significant MDR TB burden.
Read the entire page →
From page 89...
... It noted that fewer than 3 percent of MDR TB cases were being treated according to WHO standards and with quality-assured drugs, and urged member states to achieve universal access to diagnosis and treatment of MDR and XDR TB. Drug supply and quality were a major focus.
Read the entire page →
From page 90...
... It has provided equipment and supplies to laboratories and health care facilities and has supported the external evaluation of hundreds of TB diagnostic laboratories. The Russian Health Care Foundation, in collaboration with WHO and Partners In Health, helped territories receive GLC approval to treat MDR TB in 26 regional and 4 Federal TB Research Institutes, with approved projects using concessionally priced second-line 2 This section is based on the presentations of Dmitry Goliaev, Russian Health Care Foun dation; Alex Golubkov, Partners In Health; and Benjamin Potashnikov, Biocom, Russian Federation.
Read the entire page →
From page 91...
... Also, the Global Fund project helped improve infection control measures in many regions of Russia. Problems facing the foundation include the increase in MDR TB patients, insufficient application of chemotherapy standards, late detection, insufficient patient compliance with treatment, a lack of monitoring for chemotherapy, and the ineffectiveness of initiatives to encourage sick people to undergo treatment.
Read the entire page →
From page 92...
... In addition, he noted, Russia has a strong research capacity, and he suggested that the country should be involved in the search for new and more effective drugs against MDR TB. Perspective of a Russian Pharmaceutical Company Potashnikov explained how Biocom was prequalified for the production of cycloserine through collaboration with Eli Lilly.
Read the entire page →
From page 93...
... By 2011 it hopes to have its drugs registered in many of the countries of the former Soviet Union and in other countries as well.
Read the entire page →

Key Terms

  • supply chain
  • russian health
  • care foundation
  • treat mdr
  • drug facility

  • global drug
  • regulatory standards
  • facility program
  • prequalification program
  • sufficient drug

  • treating patients
  • strict national
  • research institutes
  • global fund
  • national regulatory

  • treating mdr
  • significant mdr
  • combating mdr
  • diagnostic laboratories
  • assured quality

  • control measures
  • achievable goal
  • receive glc
  • care facilities
  • nongovernmental organization

  • insufficient application
  • encourage sick
  • using concessionally
  • zintl expressed
  • proper program


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.